We are live on ! Find out more
GPP

Great Point Partners Portfolio holdings

AUM $435M
1-Year Est. Return 318.81%
This Fund
S&P 500
This Quarter Est. Return
-8.59%
1 Year Est. Return
+318.81%
3 Year Est. Return
+553.97%
5 Year Est. Return
+856.21%
10 Year Est. Return
+18,148.08%
AUM
$233M
AUM Growth
+$8.01M
Cap. Flow
+$44.8M
Cap. Flow %
19.23%
Top 10 Hldgs %
54.5%
Holding
50
New
12
Increased
13
Reduced
8
Closed
12

Top Buys

Rank Stock Value
1
EXEL icon
Exelixis
EXEL
+$16.4M
2
ELGX
Endologix Inc
ELGX
+$10.9M
3
OCRX
Ocera Therapeutics, Inc.
OCRX
+$9.02M
4
AUPH icon
Aurinia Pharmaceuticals
AUPH
+$8.8M
5
CASC
Cascadian Therapeutics, Inc.
CASC
+$7.93M

Top Sells

Rank Stock Value
1
THOR
THORATEC CORPORATION
THOR
+$9.59M
2
ARCT icon
Arcturus Therapeutics
ARCT
+$6.2M
3
NBIX icon
Neurocrine Biosciences
NBIX
+$5.24M
4
AVEO
AVEO Pharmaceuticals, Inc.
AVEO
+$4.25M
5
SCTL
Societal CDMO, Inc. Common Stock
SCTL
+$4.17M

Sector Composition

Rank Sector Weight
1 Healthcare 70.87%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VIRX
26
CALL
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$2.86M 1.23%
+1,905
New +$2.76M
ANTH
27
DELISTED
Anthera Pharmaceuticals, Inc.
ANTH
$2.75M 1.18%
178,900
-8,600
-5% -$181K
CCXI
28
DELISTED
ChemoCentryx, Inc.
CCXI
$2.18M 0.94%
+483,741
New +$2.56M
WGBS
29
DELISTED
WaferGen Bio-systems, Inc.
WGBS
$1.83M 0.79%
+84,302
New +$1.88M
TRAW icon
30
Traws Pharma
TRAW
$6.85M
$1.49M 0.64%
6
+4
+200% +$1.14M
LITS
31
Lite Strategy Inc
LITS
$32.8M
$1.09M 0.47%
7,883
– –
AMRN
32
Amarin Corp
AMRN
$299M
$1.01M 0.43%
+46,177
New +$1.5M
STRM
33
DELISTED
Streamline Health Solutions
STRM
$702K 0.3%
10,107
– –
THOR
34
DELISTED
THORATEC CORPORATION
THOR
$596K 0.26%
22,300
-337,700
-94% -$9.59M
ARCT icon
35
PUT
Arcturus Therapeutics
ARCT
$164M
$559K 0.24%
+5,171
New +$674K
TVRD
36
Tvardi Therapeutics
TVRD
$19.7M
$397K 0.17%
1,314
-4,248
-76% -$1.74M
LRMR icon
37
Larimar Therapeutics
LRMR
$397M
$331K 0.14%
+1,405
New +$318K
ARCT icon
38
Arcturus Therapeutics
ARCT
$164M
– –
-47,558
Closed -$6.2M
EXAS
39
PUT
DELISTED
Exact Sciences
EXAS
– –
-250,900
Closed -$4.27M
EYPT icon
40
EyePoint Inc
EYPT
$1.03B
– –
-37,906
Closed -$1.65M
INO icon
41
PUT
Inovio Pharmaceuticals
INO
$55.7M
– –
-10,500
Closed -$1.36M
KPTI icon
42
Karyopharm Therapeutics
KPTI
$43.5M
– –
-5,000
Closed -$3.49M
NUWE icon
43
Nuwellis
NUWE
$160K
– –
0
– -$2.38M
PLX icon
44
Protalix BioTherapeutics
PLX
$191M
– –
-16,779
Closed -$612K
SCTL
45
DELISTED
Societal CDMO, Inc. Common Stock
SCTL
– –
-580,665
Closed -$4.17M
PLXP
46
DELISTED
PLx Pharma Inc. Common Stock
PLXP
– –
-15,516
Closed -$1.2M
AVEO
47
DELISTED
AVEO Pharmaceuticals, Inc.
AVEO
– –
-232,500
Closed -$4.25M
VOLC
48
DELISTED
VOLCANO CORPORATION COM STK
VOLC
– –
-232,645
Closed -$4.1M
AVNR
49
DELISTED
AVANIR PHARMACEUTICALS, INC CL A
AVNR
– –
-450,000
Closed -$2.54M
KBIO
50
DELISTED
KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE)
KBIO
– –
-113,837
Closed -$2.08M
1
2

Similar funds

GDS
Gimbel Daniel Scott $435M AUM 78.68% 1-Year Est. Return
JWM
JPL Wealth Management Highlands Ranch, Colorado $435M AUM 16.48% 1-Year Est. Return
SWG
Summit Wealth Group White River Junction, Vermont $436M AUM 13.96% 1-Year Est. Return
SCP
Seafarer Capital Partners Larkspur, California $436M AUM 42.05% 1-Year Est. Return
VIM
VELA Investment Management New Albany, Ohio $436M AUM 15.16% 1-Year Est. Return
VDBMI
Van Den Berg Management I Austin, Texas $436M AUM 40.66% 1-Year Est. Return
ACG
Anchorage Capital Group New York $436M AUM 38.51% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM

Great Point Partners's Q3 2014 Portfolio in Review

As of Q3 2014, Great Point Partners held 50 positions worth $233M, up 3.6% from $225M the previous quarter. Its ten largest holdings account for 54% of the portfolio.

Great Point Partners deployed $44.8M of net new capital in Q3 2014, opening 12 new positions and adding to 13 existing holdings. Its largest new stake was Exelixis: 5,100,000 shares worth $7.8M.

By sector, the portfolio is most concentrated in Healthcare at 71% of assets, down from 75% a quarter earlier.

On the sell side, the largest reduction was THORATEC CORPORATION, an estimated $9.59M trimmed.

  • Great Point Partners's largest Q3 2014 buy was Exelixis: 5,100,000 shares worth $7.8M.
  • Great Point Partners added most to Endologix Inc in Q3 2014, an estimated $10.9M increase.
  • Great Point Partners's biggest Q3 2014 reduction was THORATEC CORPORATION, cutting an estimated $9.59M.
  • Great Point Partners fully exited Arcturus Therapeutics in Q3 2014, selling an estimated $6.2M.
  • Great Point Partners's ten largest holdings make up 54% of its $233M portfolio in Q3 2014.
  • Great Point Partners opened 12 new positions and closed 12 in Q3 2014.
  • Great Point Partners's portfolio value rose 3.6% quarter-over-quarter to $233M.

Based on Great Point Partners's 13F filing for Q3 2014, filed 14 Nov 2014.